Unused opportunities for correction of endocrine and metabolic disorders in polycystic ovary syndrome

DOI

https://dx.doi.org/10.18565/aig.2019.10.140-147

Chernukha G.E., Tabeeva G.I., Udovichenko M.A.
Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia, Moscow, Russia

Objective. To evaluate the effect of myo-inositol (MI) on endocrine and metabolic parameters and body composition in patients with polycystic ovary syndrome (PCOS). Subjects and methods. A total of 140 PCOS patients (mean age, 26.4±4.6) years; mean BMI, 23.2±4.3) kg/m2) received Fertina (a combination of 1000 mg of MI and 100 μg of folic acid (FA)), Orion Pharma, Finland) as 4 sachets per day. To date, a 3-month therapy cycle have been completed by 75 (53.6%) patients and 6-month course one have been completed by 57 (40.7%) women. They underwent clinical, laboratory, and instrumental examinations at baseline and after 3 and 6 months course. Results. Correction of biochemical hypeandrogenism was to progressively decrease androgen levels: total testosterone by 18%, free testosterone by 29%, and androstenedione by 15% (p <0.001) and to reduce the level of sex steroid-binding globulin by 25%. By the end of 6-month course, there were decreases in the frequency of hypeinsulinemia from 48 to 22.8% (p = 0.004), impaired glucose tolerance from 18.7 to 3.5% (p <0.001), and hyperleptinemia from 50.7% to 22% (p <0.001). The patients lost an average of 2.2 (0.9) and 4.8 (1.3) kg of body weight after 3 and 6 months course, respectively. After 6 months course, the incidence of latent obesity diagnosed on the basis of an increased percentage of adipose tissue > 30% declined by almost 2 times (from 64.7 to 39%). The decrease in total body fat mass was only 11.5%, while visceral adipose tissue was 38%. At 6 months, every three patients achieved regular menstrual cycles; pregnancy occurred in every five of those who were interested in this. Conclusion. MI administration can be viewed as an effective approach to correcting not only hormonal endocrine parameters, but also ovulatory dysfunction in patients with PCOS.

polycystic ovary syndrome

myo-inositol

Full text (in Russian)

Homburg R. Polycystic ovary syndrome from gynecological curiosity to multisystem endocrinopathy. Hum. Reprod. 1996; 11(1): 29-39. eLIBRARY ID: 10197500
Azziz R. Polycystic ovary syndrome, reproductive endocrinology and infertility. Obstet. Gynecol. 2018; 132(2): 321-36. doi: 10.1097/AOG.0000000000002698
Rojas J., Chávez M., Olivar L., Rojas M., Morillo J., Mejías J. et al. Polycystic ovary syndrome, insulin resistance, and obesity: navigating the patophysiologic labyrinth. Int. J. Reprod. Med. 2014; 2014: 719050. doi: 10.1155/2014/719050
De Sousa S.M., Norman R.J. Metabolic syndrome, diet and exercise. Best Pract. Res. Clin. Obstet. Gynaecol. 2016; 37: 140-51. doi: 10.1016/j.bpobgyn.2016.01.006.
Ткачук В.А., Воротников А.В. Молекулярные механизмы развития резистентности к инсулину. Сахарный диабет. 2014; 2: 29-40. [Tkachuk V.A., Vorotnikov A.V. Molecular mechanisms of insulin resistance development. Saharnyj diabet. 2014; 2: 29-40. (In Russian)]. doi: 10.14341/dm2014229-40
Genazzani A.D., Battaglia C., Malavasi B., Strucchi C., Tortolani F., Gamba O. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil. Steril. 2004; 81(1): 114-9. doi: 10.1016/j.fertnstert.2003.05.020
Baillargeon J.P., Iuorno M.J., Nestler J.E. Insulin sensitizers for polycystic ovary syndrome. Clin. Obstet. Gynecol. 2003; 46(2): 325-40. doi: 10.1097/00003081-200306000-00011
Strugaru A.M., Botnariu G., Agoroaei L., Grigoriu I.C., Butnaru E. Metformin induced lactic acidosis – particularities and course. Rev. Med. Chir. Soc. Med. Nat. Iasi. 2013; 117(4): 1035-42. PMID: 24502087
Agrawal A., Mahey R., Kachhawa G., Khadgawat R., Vanamail P., Kriplani A. Comparison of metformin plus myoinositol vs metformin alone in PCOS women undergoing ovulation induction cycles: randomized controlled trial. Gynecol. Endocrinol. 2019; 35(6): 511-4. doi: 10.1080/09513590.2018.1549656.
Papalou O., Victor V.M., Diamanti-Kandarakis E. Oxidative stress in polycystic ovary syndrome. Curr. Pharm. Des. 2016; 22(18): 2709-22. doi:10.2174/1381612822666160216151852
Costello M.F., Misso M.L., Balen A., Boyle J., Devoto L., Garad R.M.,et al. Evidence summaries and recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome: assessment and treatment of infertility. Hum. Reprod. Open. 2019; 2019(1): hoy021. doi: 10.1016/j.fertnstert.2018.05.004
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril. 2004; 81(1): 19-25. DOI: 10.1093/humrep/deh098
Найдукова А.А., Каприна Е.К., Иванец Т.Ю., Чернуха Г.Е. Возрастные аспекты оценки уровня антимюллерова гормона при синдроме поликистозных яичников. Акушерство и гинекология. 2017; 3: 95-100. [Naidukova A.A., Kaprina E.K., Ivanets T.Yu., Chernukha G.E. Age-related aspects of estimation of AMH levels in polycystic ovary syndrome. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2017; (3): 95-100. (in Russian)]. https://dx.doi.org/10.18565/aig.2017.3.95-100
Ovalle F., Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil. Steril. 2002; 77(6): 1095-105. doi: 10.1016/s0015-0282(02)03111-4
Блинова И.В. Функциональное состояние эндотелия и особенности эндокринно-метаболического профиля больных с различными фенотипами синдрома поликистозных яичников: автореф. дисс. … канд. мед. наук. М.; 2009. [Blinova I.V. Funkcional’noe sostojanie jendotelija i osobennosti jendokrinno-metabolicheskogo profilja bol’nyh s razlichnymi fenotipami sindroma polikistoznyh jaichnikov: avtoref. diss. … kand. med. nauk. M.; 2009. (In Russian)].
Kunjara S., McLean P., Greenbaum A.L., Rademacher T.W. Insight into the role of inositol phosphoglycans in insulin response and the regulation of glucose and lipid metabolism illustrated by the response of adipocytes from two strains of rats. Mol. Genet. Metab. 2008; 94(2): 263-6. doi: 10.1016/j.ymgme.2008.02.006.
Fisher F.M., McTernan P.G., Valsamakis G., Chetty R., Harte A.L., Anwar A.J. et al. Differences in adiponectin protein expression: effect of fat depots and type 2 diabetic status. Horm. Metab. Res. 2002; 34(11-12): 650-4. doi: 10.1055/s-2002-38246
McTernan P.G., McTernan C.L., Chetty R., Jenner K., Fisher F.M., Lauer M.N. et al. Increased resistin gene and protein expression in human abdominal adipose tissue. J. Clin. Endocrinol. Metab. 2002; 87(5): 2407.
Кологривова И.В. Висцеральное ожирение и кардиометаболический риск: особенности гормональной и иммунной регуляции. Ожирение и метаболизм. 2017; 14(3): 3-10. [Kologrivova I.V., Vinnitskaya I.V., Koshelskaya O.A., Suslova T.E. Visceral obesity and cardiometabolic risk: features of hormonal and immune regulation. Ozhirenie i metabolism. 2017; 14(3): 3-10. (In Russian)]. doi: 10.14341/omet201733-10
Мазаева Н.А. Жировая ткань, лептин и нервная анорексия. Психиатрия и психофармакотерапия им. П.Б. Ганнушкина. 2008; 10(2): 18-28. [Mazaeva N.A. Zhirovaja tkan’, leptin i nervnaja anoreksija. Psihiatrija i psihofarmakoterapija im. P.B. Gannushkina. 2008; 10(2): 18-28.(In Russian)].eLIBRARY ID: 10441380
Laganà A.S., Garzon S., Casarin J., Franchi M., Ghezzi F. Inositol in polycystic ovary syndrome: restoring fertility through a pathophysiology- based approach. Trends Endocrinol. Metab. 2018; 29(11): 768-80. doi: 10.1016/j.tem.2018.09.001
Чернуха Г.Е., Купрашвили М.И., Шевцова В.Л. Применение орлистата и пиоглитазона при синдроме поликистозных яичников и ожирении. Лечащий врач. 2005; 10: 2-7. [Chernuha G.E., Kuprashvili M.I., Shevcova V.L. Primenenie orlistata i pioglitazona pri sindrome polikistoznyh jaichnikov i ozhirenii. Lechashhij vrach. 2005; 10: 2-7. (In Russian)].
Shokrpour M. Comparison of myoinositol and metformin on glycemic control, lipid profiles,and gene expression related to insulin and lipid metabolism women with polycystic ovary syndrome:a randomized controlled clinical trial. Gynecol. Endocrinol. 2019; 35(5): 406-11. doi: 10.1080/09513590.2018.1540570
Regidor P.A. Management of women with PCOS using myo-inositol and folic acid. New clinical data and review of the literature. Horm. Mol. Biol. Clin. Investig. 2018; 34(2). doi: 10.1515/hmbci-2017-0067
Romualdi D. The metabolic status modulates the effect of metformin on the antimullerian hormone-androgens-insulin interplay in obese women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2011; 96(5): E821-4. doi: 10.1210/jc.2010-1725
Pundir J., Psaroudakis D., Savnur P., Bhide P., Sabatini L., Teede H. et al. Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials. BJOG. 2018; 125(3): 385-386. doi: 10.1111/1471-0528.14811
Carlomagno G., Unfer V. Inositol safety: clinical evidences. Eur. Rev. Med. Pharmacol. Sci. 2011; 15(8): 931-6. PMID: 21845803
Heimark D., McAllister J., Larner J. Decreased myo-inositol to chiro-inositol (M/C) ratios and increased M/C epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls. Endocr. J. 2014; 61(2): 111-7. doi:10.1507/endocrj.ej13-0423

Received 25.09.2019

Accepted 04.10.2019

Galina E. Chernukha, MD, Professor, head of the Department of gynecological endocrinology of the Federal state institution “National medical research center of obstetrics, gynecology and Perinatology named after academician V. I. Kulakov” of the Ministry of health of the Russian Federation. E-mail: g_chernukha@oparina4.ru;
117997 Moscow, academician Oparin str., 4.
Gyuzyal I. Tabeeva, PhD, senior researcher of the Department of gynecological endocrinology of the Federal state institution “National medical research center of obstetrics, gynecology and Perinatology named after academician V. I. Kulakov” of the Ministry of health of the Russian Federation. E-mail:doctor.gtab@gmail.com;
117997, Moscow, academician Oparin str., 4.
Maria A. Udovichenko, graduate student of the Department of Gynecological Endocrinology of the Federal State Budgetary Institution “National Medical Research Center
for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakova ”of the Ministry of Health of the Russian Federation. E-mail: m_udovichenko@oparina4.ru;
117997, Moscow, st. Academician Oparin, d. 4.

For citation: Chernukha G.E., Tabeeva G.I., Udovichenko M.A.Unused opportunities for correction of endocrine and metabolic disorders in polycystic ovary syndrome.
Akusherstvo i Ginekologiya/ Obstetrics and gynecology. 2019; 10: 140-47. (In Russian).
https://dx.doi.org/10.18565/aig.2019.10.140-147

Unused opportunities for correction of endocrine and metabolic disorders in polycystic ovary syndrome

Chernukha G.E., Tabeeva G.I., Udovichenko M.A.

Keywords

References

About the Authors

Similar Articles